These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 35533262)

  • 1. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse.
    Short NJ; Kantarjian H; Ravandi F; Konopleva M; Jain N; Kanagal-Shamanna R; Patel KP; Macaron W; Kadia TM; Wang S; Jorgensen JL; Khoury JD; Yilmaz M; Kebriaei P; Takahashi K; Garcia-Manero G; Daver N; Post SM; Huang X; Kornblau SM; Pelletier S; Flores W; Matthews J; Garris R; Jabbour E
    Blood Adv; 2022 Jul; 6(13):4006-4014. PubMed ID: 35533262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concordance of Next-Generation Sequencing and Multiparametric Flow Cytometry Methods for Detecting Measurable Residual Disease in Adult Acute Lymphoblastic Leukemia: Optimizing Prediction of Clinical Outcomes From a Single-Center Study.
    Ashouri K; Nittur V; Ginosyan AA; Hwang J; Adnani B; Chen D; Savitala-Damerla L; Schiff K; Chaudhary P; Kovach AE; Ladha A; Siddiqi I; Ali A; Woan K; Tam E; Yaghmour G
    Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):e59-e66.e2. PubMed ID: 38061959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.
    Pulsipher MA; Carlson C; Langholz B; Wall DA; Schultz KR; Bunin N; Kirsch I; Gastier-Foster JM; Borowitz M; Desmarais C; Williamson D; Kalos M; Grupp SA
    Blood; 2015 May; 125(22):3501-8. PubMed ID: 25862561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
    Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Measurable Residual Disease in Pediatric B-Lymphoblastic Leukemia Using Multiparametric Flow Cytometry and Next-Generation Sequencing.
    Hwang SM; Oh I; Kwon SR; Lee JS; Seong MW
    Ann Lab Med; 2024 Jul; 44(4):354-358. PubMed ID: 38237930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How I use next-generation sequencing-MRD to plan approach and prevent relapse after HCT for children and adults with ALL.
    Muffly L; Liang EC; Dolan JG; Pulsipher MA
    Blood; 2024 Jul; 144(3):253-261. PubMed ID: 38728375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.
    Short NJ; Jabbour E; Macaron W; Ravandi F; Jain N; Kanagal-Shamanna R; Patel KP; Loghavi S; Haddad FG; Yilmaz M; Issa GC; Kebriaei P; Kornblau SM; Pelletier S; Flores W; Matthews J; Garris R; Kantarjian H
    Am J Hematol; 2023 Aug; 98(8):1196-1203. PubMed ID: 37183966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
    Wang J; Lu R; Wu Y; Jia J; Gong L; Liu X; Lu S; Wang Y; Yan C; Liu K; Zhang X; Xu L; Jiang Q; Zhao X; Shi H; Lai Y; Huang X; Ruan G; Jiang H
    Br J Haematol; 2020 Aug; 190(4):533-544. PubMed ID: 32090321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation sequencing-based MRD in adults with ALL undergoing hematopoietic cell transplantation.
    Liang EC; Dekker SE; Sabile JMG; Torelli S; Zhang A; Miller K; Shiraz P; Hayes-Lattin B; Leonard JT; Muffly L
    Blood Adv; 2023 Jul; 7(14):3395-3402. PubMed ID: 37196642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation.
    Getta BM; Devlin SM; Levine RL; Arcila ME; Mohanty AS; Zehir A; Tallman MS; Giralt SA; Roshal M
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1064-1071. PubMed ID: 28315400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia.
    Mai H; Li Q; Wang G; Wang Y; Liu S; Tang X; Chen F; Zhou G; Liu Y; Li T; Wang L; Wang C; Wen F; Liu S
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3259-3266. PubMed ID: 35918464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
    Press RD; Eickelberg G; Froman A; Yang F; Stentz A; Flatley EM; Fan G; Lim JY; Meyers G; Maziarz RT; Cook RJ
    Am J Hematol; 2019 Aug; 94(8):902-912. PubMed ID: 31124175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurable residual disease testing by next generation sequencing is more accurate compared with multiparameter flow cytometry in adults with B-cell acute lymphoblastic leukemia.
    Yan N; Wang ZL; Wang XJ; Gale RP; Zhou YL; Zhao MY; Wu LX; Liao MY; Yang J; Wang CY; Zhu JH; Jiang H; Jiang Q; Liu YR; Chang YJ; Xu LP; Zhang XH; Ma TH; Huang XJ; Ruan GR
    Cancer Lett; 2024 Aug; 598():217104. PubMed ID: 38969163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
    Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
    Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing.
    Oliva S; Genuardi E; Paris L; D'Agostino M; Rogers J; Rota-Scalabrini D; Jacob AP; Patriarca F; Luppi M; Bertazzoni P; Velluti C; Capra A; Saraci E; Rossi M; Allegra A; Mina R; Gentile M; Kirsch IR; Belotti A; Cavo M; Bruno B; Musto P; Boccadoro M; Zamagni E; Gay F
    EClinicalMedicine; 2023 Jun; 60():102016. PubMed ID: 37396800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of prognostic significance between multiparameter flow cytometry and real-time quantitative polymerase chain reaction in the detection of minimal residual disease of Philadelphia chromosome-positive acute B lymphocytic leukemia before allogeneic hematopoietic stem cell transplantation].
    Wang XY; Chang YJ; Liu YR; Qin YQ; Xu LP; Wang Y; Zhang XH; Yan CH; Sun YQ; Huang XJ; Zhao XS
    Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):116-123. PubMed ID: 33858041
    [No Abstract]   [Full Text] [Related]  

  • 17. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
    Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
    Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
    Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
    Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML).
    Patkar N; Kakirde C; Shaikh AF; Salve R; Bhanshe P; Chatterjee G; Rajpal S; Joshi S; Chaudhary S; Kodgule R; Ghoghale S; Deshpande N; Shetty D; Khizer SH; Jain H; Bagal B; Menon H; Khattry N; Sengar M; Tembhare P; Subramanian P; Gujral S
    Leukemia; 2021 May; 35(5):1392-1404. PubMed ID: 33558666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.
    Mannis GN; Martin TG; Damon LE; Andreadis C; Olin RL; Kong KA; Faham M; Hwang J; Ai WZ; Gaensler KML; Sayre PH; Wolf JL; Logan AC
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1030-1036. PubMed ID: 26899561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.